Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China
· Delayed Price · Currency is CNY 11.49
+0.04 (0.35%)
Apr 30, 2026, 3:04 PM CST
SHE:301211 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2018 |
| Operating Revenue | 451.52 | 445.8 | 437.76 | 651.42 | 511.65 | 539.75 | Upgrade
|
| Other Revenue | 7.5 | 7.5 | 8.11 | 11.61 | 3.26 | 0.87 | Upgrade
|
| Revenue | 459.02 | 453.31 | 445.86 | 663.03 | 514.91 | 540.62 | Upgrade
|
| Revenue Growth (YoY) | 8.71% | 1.67% | -32.75% | 28.77% | -4.76% | -8.82% | Upgrade
|
| Cost of Revenue | 364.36 | 358.41 | 317.79 | 397.55 | 369.78 | 358.33 | Upgrade
|
| Gross Profit | 94.66 | 94.9 | 128.07 | 265.47 | 145.13 | 182.3 | Upgrade
|
| Selling, General & Admin | 64.54 | 64.55 | 61.71 | 62.09 | 47.9 | 38.54 | Upgrade
|
| Research & Development | 24.1 | 25.18 | 32.94 | 52.77 | 19.84 | 18.28 | Upgrade
|
| Other Operating Expenses | 5.02 | 5.24 | 3.77 | 5.92 | 3.96 | 5.89 | Upgrade
|
| Operating Expenses | 93.77 | 95.09 | 98.44 | 120.07 | 69.78 | 64.23 | Upgrade
|
| Operating Income | 0.89 | -0.19 | 29.64 | 145.4 | 75.35 | 118.06 | Upgrade
|
| Interest Expense | -0.18 | -0.18 | -0.31 | -0.31 | -0.34 | - | Upgrade
|
| Interest & Investment Income | 27.6 | 28.11 | 51.33 | 47.84 | 61.02 | 13.1 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.55 | -1.55 | 3.34 | 3.36 | 4.78 | -3.62 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.6 | -0.45 | -0.63 | -0.39 | -0.44 | 0.13 | Upgrade
|
| EBT Excluding Unusual Items | 23.16 | 25.74 | 83.36 | 195.9 | 140.36 | 127.68 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13.3 | 12.97 | 14.58 | 4.02 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.01 | 0.01 | - | 0.18 | 0.04 | -0.07 | Upgrade
|
| Asset Writedown | -0.02 | -0.02 | -0.11 | -2.58 | -0.66 | -0 | Upgrade
|
| Other Unusual Items | 2.56 | 2.56 | 2.58 | 5.3 | 7.69 | 11.58 | Upgrade
|
| Pretax Income | 39.01 | 41.26 | 100.42 | 202.82 | 147.44 | 139.18 | Upgrade
|
| Income Tax Expense | 5.21 | 6.35 | 8.87 | 26.7 | 21.65 | 17.54 | Upgrade
|
| Earnings From Continuing Operations | 33.8 | 34.91 | 91.55 | 176.12 | 125.79 | 121.65 | Upgrade
|
| Net Income | 33.8 | 34.91 | 91.55 | 176.12 | 125.79 | 121.65 | Upgrade
|
| Net Income to Common | 33.8 | 34.91 | 91.55 | 176.12 | 125.79 | 121.65 | Upgrade
|
| Net Income Growth | -47.59% | -61.87% | -48.02% | 40.01% | 3.41% | -27.62% | Upgrade
|
| Shares Outstanding (Basic) | 423 | 436 | 416 | 419 | 415 | 311 | Upgrade
|
| Shares Outstanding (Diluted) | 423 | 436 | 416 | 419 | 415 | 311 | Upgrade
|
| Shares Change (YoY) | -4.19% | 4.87% | -0.60% | 0.97% | 33.19% | -1.01% | Upgrade
|
| EPS (Basic) | 0.08 | 0.08 | 0.22 | 0.42 | 0.30 | 0.39 | Upgrade
|
| EPS (Diluted) | 0.08 | 0.08 | 0.22 | 0.42 | 0.30 | 0.39 | Upgrade
|
| EPS Growth | -45.29% | -63.64% | -47.71% | 38.66% | -22.36% | -26.88% | Upgrade
|
| Free Cash Flow | -45.72 | -44.78 | -68.36 | -49.47 | 174.84 | 102.92 | Upgrade
|
| Free Cash Flow Per Share | -0.11 | -0.10 | -0.16 | -0.12 | 0.42 | 0.33 | Upgrade
|
| Dividend Per Share | 0.060 | 0.060 | 0.250 | 0.331 | 0.230 | 0.172 | Upgrade
|
| Dividend Growth | -76.00% | -76.00% | -24.47% | 43.98% | 33.35% | - | Upgrade
|
| Gross Margin | 20.62% | 20.93% | 28.73% | 40.04% | 28.18% | 33.72% | Upgrade
|
| Operating Margin | 0.19% | -0.04% | 6.65% | 21.93% | 14.63% | 21.84% | Upgrade
|
| Profit Margin | 7.36% | 7.70% | 20.53% | 26.56% | 24.43% | 22.50% | Upgrade
|
| Free Cash Flow Margin | -9.96% | -9.88% | -15.33% | -7.46% | 33.96% | 19.04% | Upgrade
|
| EBITDA | 47.62 | 42 | 53.68 | 165.63 | 95.73 | 137.43 | Upgrade
|
| EBITDA Margin | 10.38% | 9.26% | 12.04% | 24.98% | 18.59% | 25.42% | Upgrade
|
| D&A For EBITDA | 46.73 | 42.19 | 24.05 | 20.23 | 20.38 | 19.37 | Upgrade
|
| EBIT | 0.89 | -0.19 | 29.64 | 145.4 | 75.35 | 118.06 | Upgrade
|
| EBIT Margin | 0.19% | -0.04% | 6.65% | 21.93% | 14.63% | 21.84% | Upgrade
|
| Effective Tax Rate | 13.35% | 15.39% | 8.83% | 13.16% | 14.68% | 12.60% | Upgrade
|
| Revenue as Reported | 453.31 | 453.31 | 445.86 | 663.03 | 514.91 | 540.62 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.